ACC 2022 – POISE-3: Tranexamic Acid, Bleeding and Cardiovascular Events in Non-Cardiac Surgeries

Tranexamic Acid is an antifibrinolytic which has been shown to reduce bleeding in orthopedic patients and cardiac surgery. But evidence for its use in non-cardiac surgery is still limited. 

ACC 2022 - Estudio POISE-3: Ácido tranexámico en pacientes sometidos a cirugía no cardíaca

The aim of this study was to assess whether tranexamic acid reduces the incidence of bleeding events, which include life threatening bleeding, major bleeding, or bleeding into a critical organ (superiority design) and MACE incidence assessment (non-inferiority design) at 30 days, compared against placebo. 

The study randomized 9535 patients, mean age 69, considered at risk of bleeding and cardiovascular events, 76.8% with non-orthopedic surgery. The dose of tranexamic acid was 1gr. both at the start and end of surgery. 

The use of tranexamic acid significantly reduced bleeding incidence (HR 0.76, CI95% 0.67-0.87, p.001), with no evidence of MACE reduction (HR 1.02, CI95% 092-1.14, p: 0.04) and without reaching non-inferiority.

Read also: STEMI: Can We Omit Stenting?

Within the adverse events there was higher risk of seizures (HR 3.35), with no significant differences in serious events (5.5% vs 5.1% p:0.16).

Conclusions 

In patients at risk of bleeding and cardiovascular events set to receive non-cardiac surgery, the use of tranexamic acid significantly reduces bleeding compared against placebo. Despite the low rate of MACE in both groups, non-inferiority was not reached for cardiovascular events. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the editorial board, SOLACI.org

Original Title: Poise-3: Tranexamic Acid in Patients Undergoing Noncardiac Surgery

Reference: Devereaux, P. J., Marcucci, M., Painter, T. W., Conen, D., Lomivorotov, V., Sessler, D. I., Chan, M. T. V., Borges, F. K., Martínez-Zapata, M. J., Wang, C.-Y., Xavier, D., Ofori, S. N., Wang, M. K., Efremov, S., Landoni, G., Kleinlugtenbelt, Y. V., Szczeklik, W., Schmartz, D., Garg, A. X., … POISE-3 Investigators. (2022). Tranexamic acid in patients undergoing noncardiac surgery. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2201171


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

AHA 2025 | DAPT-MVD: Extended DAPT vs. Aspirin Monotherapy After PCI in Multivessel Disease

In patients with multivessel coronary artery disease who remain stable 12 months after drug-eluting stent (DES) stenting, there is uncertainty as to prolonging dual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....